Contineum Therapeutics Financials
This page shows Contineum Therapeutics (CTNM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Equity financing rather than product revenue is funding a research-heavy, asset-light operating model as cash burn steepens.
From FY2024 to FY2025, operating cash burn widened from-$32.8M to-$55.3M , yet cash rose from$21.9M to$75.6M because financing inflows exceeded$109.0M in both years. That combination means current balance-sheet strength comes from external capital raising, not from the business turning research spending into self-funding operations.
FY2025 capital spending was only
With total liabilities of just
Financial Health Signals
Contineum Therapeutics does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Contineum Therapeutics passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 1 leverage/liquidity signals pass.
Contineum Therapeutics reported a net loss of $60.0M while operations used $55.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Contineum Therapeutics's EBITDA was -$67.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 33.8% from the prior year.
Contineum Therapeutics reported -$60.0M in net income in fiscal year 2025. This represents a decrease of 41.9% from the prior year.
Contineum Therapeutics earned -$2.17 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.5% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Contineum Therapeutics recorded an outflow of $55.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 66.5% from the prior year.
Contineum Therapeutics held $75.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Contineum Therapeutics's ROE was -23.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 1.6 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Contineum Therapeutics invested $51.5M in research and development in fiscal year 2025. This represents an increase of 34.1% from the prior year.
Contineum Therapeutics invested $231K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 55.1% from the prior year.
Not reported for fiscal year 2025.
CTNM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | N/A | N/A | $0-100.0% | $50.0M |
| R&D Expenses | N/A | $51.5M+34.1% | $38.4M+39.2% | $27.6M |
| SG&A Expenses | N/A | $16.5M+32.6% | $12.5M+97.3% | $6.3M |
| Operating Income | N/A | -$68.1M-33.7% | -$50.9M-416.6% | $16.1M |
| Interest Expense | N/A | N/A | $0-100.0% | $208K |
| Income Tax | N/A | $0 | $0-100.0% | $450K |
| Net Income | N/A | -$60.0M-41.9% | -$42.3M-286.0% | $22.7M |
| EPS (Diluted) | — | -$2.17+0.5% | -$2.18 | $0.08 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CTNM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Total Assets | $276.6M+30.0% | $212.8M+63.2% | $130.4M |
| Current Assets | $267.9M+29.8% | $206.4M+61.6% | $127.7M |
| Cash & Equivalents | $75.6M+244.5% | $21.9M+41.3% | $15.5M |
| Total Liabilities | $15.7M+5.9% | $14.8M-92.5% | $198.3M |
| Current Liabilities | $9.7M-2.3% | $10.0M+81.9% | $5.5M |
| Total Equity | $261.0M+31.8% | $198.1M+391.5% | -$67.9M |
| Retained Earnings | -$177.4M-51.1% | -$117.4M-56.2% | -$75.1M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
CTNM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Operating Cash Flow | -$53.0M | -$55.3M-68.4% | -$32.8M-269.8% | $19.3M |
| Capital Expenditures | $458K | $231K-55.1% | $514K+24.2% | $414K |
| Free Cash Flow | -$53.5M | -$55.5M-66.5% | -$33.4M-276.2% | $18.9M |
| Investing Cash Flow | -$67.0M | -$3.7M+94.7% | -$69.7M-6.4% | -$65.6M |
| Financing Cash Flow | $113.9M | $112.7M+3.4% | $109.0M+94.0% | $56.2M |
| Share Buybacks | N/A | N/A | $0-100.0% | $28K |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CTNM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Operating Margin | N/A | N/A | 32.1% |
| Net Margin | N/A | N/A | 45.4% |
| Return on Equity | -23.0%-1.6pp | -21.3% | N/A |
| Return on Assets | -21.7%-1.8pp | -19.9%-37.3pp | 17.4% |
| Current Ratio | 27.50+6.8x | 20.69-2.6x | 23.29 |
| Debt-to-Equity | 0.060.0x | 0.07 | N/A |
| FCF Margin | N/A | N/A | 37.9% |
Not reported in any period shown, so not listed: Gross Margin.
Similar Companies
Where Contineum Therapeutics Ranks
Frequently Asked Questions
Is Contineum Therapeutics profitable?
No, Contineum Therapeutics (CTNM) reported a net income of -$60.0M in fiscal year 2025.
What is Contineum Therapeutics's EBITDA?
Contineum Therapeutics (CTNM) had EBITDA of -$67.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Contineum Therapeutics's return on equity (ROE)?
Contineum Therapeutics (CTNM) has a return on equity of -23.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Contineum Therapeutics's free cash flow?
Contineum Therapeutics (CTNM) recorded an outflow of $55.5M in free cash flow during fiscal year 2025. This represents a -66.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Contineum Therapeutics's operating cash flow?
Contineum Therapeutics (CTNM) recorded an outflow of $55.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Contineum Therapeutics's total assets?
Contineum Therapeutics (CTNM) had $276.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Contineum Therapeutics's capital expenditures?
Contineum Therapeutics (CTNM) invested $231K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Contineum Therapeutics spend on research and development?
Contineum Therapeutics (CTNM) invested $51.5M in research and development during fiscal year 2025.
What is Contineum Therapeutics's current ratio?
Contineum Therapeutics (CTNM) had a current ratio of 27.50 as of fiscal year 2025, which is generally considered healthy.
What is Contineum Therapeutics's debt-to-equity ratio?
Contineum Therapeutics (CTNM) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Contineum Therapeutics's return on assets (ROA)?
Contineum Therapeutics (CTNM) had a return on assets of -21.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Contineum Therapeutics's cash runway?
Based on fiscal year 2025 data, Contineum Therapeutics (CTNM) had $75.6M in cash against an annual operating cash burn of $55.3M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Contineum Therapeutics's Piotroski F-Score?
Contineum Therapeutics (CTNM) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Contineum Therapeutics's earnings high quality?
Contineum Therapeutics (CTNM) reported a net loss of $60.0M while operations used $55.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.